FibroGen’s (FGEN) “Market Perform” Rating Reiterated at William Blair

FibroGen (NASDAQ:FGEN)‘s stock had its “market perform” rating reissued by equities researchers at William Blair in a research note issued on Wednesday,RTT News reports.

Separately, StockNews.com assumed coverage on FibroGen in a research note on Wednesday, November 6th. They issued a “hold” rating on the stock.

FibroGen Price Performance

FGEN stock opened at $0.37 on Wednesday. The company’s 50-day moving average price is $0.37 and its two-hundred day moving average price is $0.72. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to the consensus estimate of $34.00 million. During the same quarter in the previous year, the business posted ($0.52) EPS. On average, sell-side analysts expect that FibroGen will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC grew its stake in FibroGen by 34.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after purchasing an additional 860,854 shares during the period. AQR Capital Management LLC lifted its holdings in FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of FibroGen in the third quarter valued at approximately $307,000. XTX Topco Ltd purchased a new position in shares of FibroGen during the 2nd quarter valued at $424,000. Finally, Cubist Systematic Strategies LLC grew its position in FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares in the last quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.